|
|
|
Genaissance Signs with AstraZeneca
|
Business New Haven
1/7/2002
By: BNH
|
NEW HAVEN - Genaissance Pharmaceuticals, Inc. (NASDAW: GNSC) announced that it has entered into an agreement with AstraZeneca PLC (NYSE: AZN) in which the companies will apply Genaissance technology to one of AstraZeneca's target discovery programs. AstraZeneca will gain access to specific HAP(TM) Markers from Genaissance's HAP(TM) Database and also utilize the DecoGen® Informatics platform for correlating HAP(TM) Markers to disease and/or clinical outcomes.
“We are very pleased to become partners with one of the leading pharmaceutical companies in the world,'' said Gualberto Ruano, M.D., Ph.D., and chief executive officer of Genaissance. “We look forward to collaborating with AstraZeneca to enhance their target discovery and validation research, and welcome this opportunity to apply our HAP(TM) Technology in a new way for these discovery applications.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
